Landmark Nature Publication Demonstrates the Power of the Fluidigm Hyperion Imaging System to Identify Novel Cellular Signatures That Correlate with Distinct Clinical Outcomes - Seite 2
Key findings from the study include:
- The Fluidigm Hyperion Imaging System enables single-cell resolution of protein expression profiles and spatial location within a complex tissue, such as breast cancer.
- Analysis of single-cell protein expression and spatial data identified 14 main clusters containing common cellular subtypes and also identified 18 single-cell pathology (SCP) groups that differed from the traditional pathology-based subtypes and had distinct clinical outcomes between patients and between other SCP subgroups in the same pathology classification and other SCP subgroups with similar cellular composition but distinct architecture.
“This landmark study is the first to demonstrate the potential clinical value of highly multiplexed Imaging Mass Cytometry to identify breast cancer subtypes that correlate with clinical outcomes,” said Chris Linthwaite, President and CEO of Fluidigm. “By shedding new light with single-cell spatial images and data about the features of the tumor microenvironment, we believe this study will further increase adoption of IMC in translational and clinical research to deliver better predictive and personalized approaches to cancer care in the future.”
About Imaging Mass Cytometry
Imaging Mass Cytometry is setting a new standard in tissue imaging, significantly simplifying high-multiplex panel design and eliminating the impact of tissue autofluorescence by using highly pure
metal tags for which signals are separated by mass instead of by wavelength. Incorporating an easy-to-use immunohistochemistry workflow that simultaneously detects many proteins in a single scan,
IMC is ideal for uncovering new insights in health and disease and empowering the development of better diagnostics and more effective therapies.
Lesen Sie auch
About Fluidigm
Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in
translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic
solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading
academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more
information, visit fluidigm.com.